Secukinumab in psoriasis: Randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)

British Journal of Dermatology

Volumn 173, Issue 3, 2015, Pages 777-787

  Thaci D ^a   Humeniuk, J ^b   Frambach, Y ^c   Bissonnette, R ^d   Goodman, J J ^e   Shevade, S ^f   Gong, Y ^g   Papavassilis, C ^h  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Humeniuk Dermatology   (United States)

^c Hanse Klinik GmbH   (Germany)

^d INNOVADERM RESEARCH   (Canada)

^e Paley Institute   (United States)

^f Novartis Healthcare Private Limited   (India)

^g Novartis Beijing Novartis Pharma Co Ltd   (China)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

SECUKINUMAB; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLICULITIS; HEADACHE; HUMAN; HYPERTENSION; IMMUNOGENICITY; INJECTION SITE PAIN; INTERTRIGO; MALE; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SKIN ALLERGY; SKIN DEFECT; THRUSH; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; PSORIASIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 84937984975     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13814     Document Type: Article

References (40)

1. Gottlieb AB, Dann F,. Comorbidities in patients with psoriasis. Am J Med 2009; 122: 1150.e1-9.
2. Griffiths CE, Christophers E, Barker JN, et al., A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007; 156: 258-62.
3. Kim N, Thrash B, Menter A,. Comorbidities in psoriasis patients. Semin Cutan Med Surg 2010; 29: 10-15.
4. Parisi R, Symmons DP, Griffiths CE, et al., Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-85.
5. Guenther L, Gulliver W,. Psoriasis comorbidities. J Cutan Med Surg 2009; 13 (Suppl. 2): S77-87.
6. Langley RG, Krueger GG, Griffiths CE,. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 (Suppl. 2): ii18-23.
7. Sampogna F, Tabolli S, Abeni D, et al., Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol 2012; 92: 299-303.
8. Krueger JG, Bowcock A,. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64 (Suppl. 2): ii30-6.
9. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.
10. Toichi E, Torres G, McCormick TS, et al., An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006; 177: 4917-26.
11. Weger W,. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010; 160: 810-20.
12. Leonardi CL, Kimball AB, Papp KA, et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
13. Leonardi CL, Powers JL, Matheson RT, et al., Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
14. Menter A, Tyring SK, Gordon K, et al., Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
15. Reich K, Nestle FO, Papp K, et al., Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74.
16. Cai Y, Shen X, Ding C, et al., Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity 2011; 35: 596-610.
17. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al., Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011; 131: 677-87.
18. Lin AM, Rubin CJ, Khandpur R, et al., Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011; 187: 490-500.
19. Girolomoni G, Mrowietz U, Paul C,. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 2012; 167: 717-24.
20. Hueber W, Patel DD, Dryja T, et al., Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72.
21. Kagami S, Rizzo HL, Lee JJ, et al., Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010; 130: 1373-83.
22. Kryczek I, Bruce AT, Gudjonsson JE, et al., Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008; 181: 4733-41.
23. Leonardi C, Matheson R, Zachariae C, et al., Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-9.
24. Papp KA, Langley RG, Sigurgeirsson B, et al., Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013; 168: 412-21.
25. Papp KA, Leonardi C, Menter A, et al., Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-9.
26. Rich P, Sigurgeirsson B, Thaci D, et al., Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013; 168: 402-11.
27. van der Fits L, Mourits S, Voerman JS, et al., Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009; 182: 5836-45.
28. Langley RG, Elewski BE, Lebwohl M, et al., Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014; 371: 326-38.
29. Mrowietz U, Toth D, Leonardi C, et al., Secukinumab retreatment-as-needed maintenance regimen: efficacy and safety outcomes from the SCULPTURE study. E-poster presentation at the 72nd American Academy of Dermatology Annual Meeting, Denver, CO, U.S.A., 21-25 March 2014; poster #8229.
30. Brezinski EA, Armstrong AW,. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS ONE 2012; 7: e33486.
31. Cassano N, Loconsole F, Miracapillo A, et al., Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group. Int J Immunopathol Pharmacol 2010; 23: 797-802.
32. Leonardi C, Sobell JM, Crowley JJ, et al., Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol 2012; 167: 658-67.
33. Papp KA, Langley RG, Lebwohl M, et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
34. van den Reek JM, van Lümig PP, Kievit W, et al., Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice. J Dermatolog Treat 2013; 24: 361-8.
35. Langley RG, Feldman SR, Nyirady J, et al., The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 2015; 26: 23-31.
36. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
37. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
38. Newcombe RG,. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857-72.
39. Lucka TC, Pathirana D, Sammain A, et al., Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol 2012; 26: 1331-44.
40. Mrowietz U, Kragballe K, Reich K, et al., Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.